aTyr Pharma, Inc. $ATYR Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP raised its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) by 272.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,630,638 shares of the company’s stock after purchasing an additional 1,923,907 shares during the quarter. GSA Capital Partners LLP owned about 2.68% of aTyr Pharma worth $2,060,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System acquired a new position in shares of aTyr Pharma during the second quarter worth about $28,000. Legal & General Group Plc acquired a new position in shares of aTyr Pharma during the second quarter worth about $49,000. Prudential Financial Inc. acquired a new position in shares of aTyr Pharma during the second quarter worth about $63,000. Oxford Asset Management LLP acquired a new position in shares of aTyr Pharma during the second quarter worth about $70,000. Finally, Creative Planning acquired a new position in shares of aTyr Pharma during the second quarter worth about $74,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.67.

aTyr Pharma Stock Down 7.0%

Shares of aTyr Pharma stock opened at $0.48 on Wednesday. The firm has a market cap of $47.36 million, a price-to-earnings ratio of -0.66 and a beta of 0.66. aTyr Pharma, Inc. has a 52-week low of $0.40 and a 52-week high of $7.29. The company’s 50-day simple moving average is $0.80 and its 200-day simple moving average is $0.80.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Equities research analysts anticipate that aTyr Pharma, Inc. will post -0.66 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.